Advanced glycation end-products and the progress of diabetic vascular complications
Jazyk angličtina Země Česko Médium print
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
PubMed
15046548
Knihovny.cz E-zdroje
- MeSH
- arterioskleróza etiologie patofyziologie MeSH
- diabetes mellitus metabolismus patofyziologie MeSH
- glykosylace MeSH
- guanidiny terapeutické užití MeSH
- hyperglykemie komplikace metabolismus patofyziologie MeSH
- komplikace diabetu * MeSH
- lidé MeSH
- nemoci cév farmakoterapie etiologie MeSH
- oxidační stres fyziologie MeSH
- peptidy metabolismus MeSH
- produkty pokročilé glykace krev metabolismus fyziologie MeSH
- pyridoxamin terapeutické užití MeSH
- receptor pro konečné produkty pokročilé glykace MeSH
- receptory imunologické fyziologie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
- Názvy látek
- guanidiny MeSH
- peptidy MeSH
- pimagedine MeSH Prohlížeč
- produkty pokročilé glykace MeSH
- pyridoxamin MeSH
- receptor pro konečné produkty pokročilé glykace MeSH
- receptory imunologické MeSH
Epidemiological studies have confirmed that hyperglycemia is the most important factor in the onset and progress of vascular complications, both in Type 1 and 2 diabetes mellitus. The formation of advanced glycation end-products (AGEs) correlates with glycemic control. The AGE hypothesis proposes that accelerated chemical modification of proteins by glucose during hyperglycemia contributes to the pathogenesis of diabetic complications including nephropathy, retinopathy, neuropathy and atherosclerosis. Recent studies have shown that increased formation of serum AGEs exists in diabetic children and adolescents with or without vascular complications. Furthermore, the presence of diabetic complications in children correlates with elevated serum AGEs. The level of serum AGEs could be considered as a marker of later developments of vascular complications in children with Type 1 and 2 diabetes mellitus. The careful metabolic monitoring of young diabetics together with monitoring of serum AGEs can provide useful information about impending AGE-related diabetic complications. It is becoming clear that anti-AGE strategies may play an important role in the treatment of young and older diabetic patients. Several potential drug candidates such as AGE inhibitors have been reported recently.